Your Daily Venture Capital Briefing

OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds

• OrbiMed, a leading global healthcare investment firm, has successfully raised $3 billion across two new private equity funds: OrbiMed Private Investments X and OrbiMed Asia Partners VI. OrbiMed Private Investments X secured over $1.9 billion for U.S. and European life sciences venture capital, while OrbiMed Asia Partners VI raised over $1 billion for healthcare growth equity and venture capital in Asia, aiming to build leading companies in biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.

  Orbimed

• Fintech giant Ramp has confirmed a $1.85 billion primary financing round, maintaining its $60 billion valuation, with Dragoneer Investment Group, Thrive Capital, Sands Capital, and Avenir Growth co-leading the investment. The company now reports over $2 billion in annualized revenue and is cash flow positive, demonstrating a 25% faster growth rate compared to the same period last year.

  Prnewswire

• In a contrasting regional trend, venture capital funding in North Carolina's Research Triangle plummeted to $99 million in Q3 2026, a sharp decline from its average quarterly total of $498 million across 37 deals. The latest Venture Monitor report indicates only 29 funding rounds were reported, with nearly all staying under $5 million, highlighting a localized concentration of smaller deals despite national trends of larger median Series D rounds.

  Technical Ly